European shares hit two-week low on global tech rout; earnings in spotlight

European equities, as measured by the STOXX 600, declined to a two-week low, primarily due to a selloff in technology stocks driven by resurfacing global overvaluation concerns following record runs fueled by AI enthusiasm and a hawkish Federal Reserve outlook. Amid this broader market pressure, corporate earnings were mixed, with Novo Nordisk gaining after accepting U.S. price caps despite a lowered profit forecast, Vestas rising on strong operating profit, while Ambu and Nexi saw significant declines on disappointing results, and BMW advanced after boosting profit margins.

Analysis

European equities, as measured by the STOXX 600, declined 0.3% to a two-week low, primarily driven by a 0.9% selloff in technology stocks. This downturn reflects resurfacing global overvaluation concerns, particularly in AI-fueled tech, exacerbated by a hawkish Federal Reserve stance on interest rates. The absence of official U.S. data to support current market momentum is intensifying investor scrutiny of lofty valuations.

The European earnings season presents a mixed picture, despite an overall improved outlook for corporate health compared to earlier periods. However, European firms are underperforming U.S. peers, with falling revenues prompting increased focus on cost savings and restructuring initiatives. This divergence highlights underlying pressures on profitability despite some positive individual reports.

Individual corporate results varied significantly: Novo Nordisk shares climbed 1.8% after accepting U.S. drug price caps, despite a lowered full-year profit forecast. Vestas surged 12.7% on better-than-expected Q3 operating profit, while BMW gained 1.8% by boosting core profit margins through R&D cuts. Conversely, Ambu slumped 13.4% due to below-consensus results, and Nexi slid 7.3% after narrowly missing core profit expectations.

Key Decisions for Investors

• Investors should reassess exposure to high-valuation technology stocks, particularly those driven by AI narratives, given resurfacing overvaluation concerns and a hawkish monetary policy environment.
• Maintain a selective approach to European equities, favoring companies with strong operational execution and clear profitability drivers, while exercising caution with firms reporting missed earnings or revenue pressures.
• Monitor the long-term impact of regulatory changes, such as U.S. drug price caps, and scrutinize corporate guidance for shifts in profitability and strategic adjustments.